143 related articles for article (PubMed ID: 25756669)
1. More effective DPP4 inhibitors as antidiabetics based on sitagliptin applied QSAR and clinical methods.
Buiu C; Avram S; Duda-Seiman D; Milac AL; Duda-Seiman C; Pacureanu L; Borcan F
Curr Comput Aided Drug Des; 2014; 10(3):237-49. PubMed ID: 25756669
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
Musoev A; Numonov S; You Z; Gao H
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
[TBL] [Abstract][Full Text] [Related]
3. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
Abel T; Fehér J
Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
[TBL] [Abstract][Full Text] [Related]
4. Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.
Vélez de Mendizábal N; Strother RM; Farag SS; Broxmeyer HE; Messina-Graham S; Chitnis SD; Bies RR
Clin Pharmacokinet; 2014 Mar; 53(3):247-259. PubMed ID: 24142388
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
7. Clinical review of sitagliptin: a DPP-4 inhibitor.
Garg K; Tripathi CD; Kumar S
J Assoc Physicians India; 2013 Sep; 61(9):645-9. PubMed ID: 24772702
[TBL] [Abstract][Full Text] [Related]
8. Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes.
Krishna R; Herman G; Wagner JA
AAPS J; 2008 Jun; 10(2):401-9. PubMed ID: 18686043
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study.
Goodwin SR; Reeds DN; Royal M; Struthers H; Laciny E; Yarasheski KE
J Clin Endocrinol Metab; 2013 Feb; 98(2):743-51. PubMed ID: 23264399
[TBL] [Abstract][Full Text] [Related]
10. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of molecular interaction of sitagliptin with human DPP
Gonzatti MB; Júnior JEM; Rocha AJ; de Oliveira JS; Evangelista AJJ; Fonseca FMP; Ceccatto VM; de Oliveira AC; da Cruz Freire JE
Adv Med Sci; 2023 Sep; 68(2):402-408. PubMed ID: 37837799
[TBL] [Abstract][Full Text] [Related]
13. Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.
Furukawa S; Kumagi T; Miyake T; Ueda T; Niiya T; Nishino K; Murakami S; Murakami M; Matsuura B; Onji M
Endocr J; 2012; 59(4):329-33. PubMed ID: 22277726
[TBL] [Abstract][Full Text] [Related]
14. New treatments for type 2 diabetes--the DPP4 inhibitors.
Gadsby R
Prim Care Diabetes; 2007 Dec; 1(4):209-11. PubMed ID: 18632049
[TBL] [Abstract][Full Text] [Related]
15. [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Jermendy G
Orv Hetil; 2011 Sep; 152(37):1471-6. PubMed ID: 21893477
[TBL] [Abstract][Full Text] [Related]
16. [Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2013 Oct; 68(10):504-10. PubMed ID: 24298724
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.
Pham DQ; Nogid A; Plakogiannis R
Am J Health Syst Pharm; 2008 Mar; 65(6):521-31. PubMed ID: 18319497
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin: a review.
Subbarayan S; Kipnes M
Expert Opin Pharmacother; 2011 Jul; 12(10):1613-22. PubMed ID: 21651449
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Bailey CJ; Green BD; Flatt PR
Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Soliman AR; Fathy A; Khashab S; Shaheen N; Soliman MA
Exp Clin Transplant; 2013 Dec; 11(6):494-8. PubMed ID: 24344941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
